Ranolazine for the treatment of heart failure with preserved ejection fraction: Background, aims, and design of the RALI-DHF study

Clinical Cardiology

Volumn 34, Issue 7, 2011, Pages 426-432

  Jacobshagen, Claudius ^a   Belardinelli, Luiz ^b   Hasenfuss, Gerd ^a   Maier, Lars S ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Gilead Palo Alto Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; PLACEBO; RANOLAZINE;

ADULT; ARTICLE; BLOOD FLOW VELOCITY; CARDIAC PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLE; DIASTOLIC HEART FAILURE; DOPPLER ECHOCARDIOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEART CATHETERIZATION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE DP-DT; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FILLING; HEART MUSCLE OXYGEN CONSUMPTION; HEART MUSCLE RELAXATION; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; TRANSLATIONAL RESEARCH;

ACETANILIDES; ADMINISTRATION, ORAL; BIOLOGICAL MARKERS; CARDIOVASCULAR AGENTS; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY, DOPPLER; GERMANY; HEART CATHETERIZATION; HEART FAILURE, DIASTOLIC; HUMANS; INFUSIONS, INTRAVENOUS; NATRIURETIC PEPTIDE, BRAIN; OXYGEN CONSUMPTION; PEPTIDE FRAGMENTS; PIPERAZINES; PLACEBO EFFECT; PROSPECTIVE STUDIES; RECOVERY OF FUNCTION; RESEARCH DESIGN; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT; VENTRICULAR PRESSURE;

EID: 79960430593     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20897     Document Type: Article

References (28)

1. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006; 355: 251-259. (Pubitemid 44079340)
2. Paulus WJ, Tschöpe C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007; 28: 1539-1550.
3. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006; 355: 260-269. (Pubitemid 44088349)
4. Hasenfuss G, Schillinger W, Lehnart SE, et al. Relationship between Na+-Ca2+-exchanger protein levels and diastolic function of failing human myocardium. Circulation. 1999; 99: 641-648. (Pubitemid 29077705)
5. Hasenfuss G, Pieske B., Calcium cycling in congestive heart failure. J Mol Cell Cardiol. 2002; 34: 951-969. (Pubitemid 35316143)
6. Schmidt U, Hajjar RJ, Helm PA, et al. Contribution of abnormal sarcoplasmic reticulum ATPase activity to systolic and diastolic dysfunction in human heart failure. J Mol Cell Cardiol. 1998; 30: 1929-1937. (Pubitemid 28495319)
7. Yancy CW, Lopatin M, Stevenson LW, et al. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol. 2006; 47: 76-84. (Pubitemid 43005168)
8. Gorelik O, Moznino-Sarafian D, Shteinshnaider M, et al. Clinical variables affecting survival in patients with decompensated diastolic versus systolic heart failure. Clin Res Cardiol 2009;1; 98: 224-232.
9. Hadano Y, Murata K, Yamamoto T, et al. Usefulness of mitral annular velocity in predicting exercise tolerance in patients with impaired left ventricular systolic function. Am J Cardiol. 2006; 97: 1025-1028.
10. Skaluba SJ, Litwin SE., Mechanisms of exercise intolerance: insights from tissue Doppler imaging. Circulation. 2004; 109: 972-977. (Pubitemid 38282849)
11. Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006; 27: 2338-2345. (Pubitemid 44453578)
12. Paulus WJ, van Ballegoij JJ., Treatment of heart failure with normal ejection fraction: an inconvenient truth! J Am Coll Cardiol. 2010; 55: 526-537.
13. Kamp O, Metra M, De Keulenaer G, et al. Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. Clin Res Cardiol. 2010; 99: 75-82.
14. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007; 297: 1775-1783. (Pubitemid 46658646)
15. Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004; 43: 1375-1382. (Pubitemid 38496341)
16. Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004; 291: 309-316. (Pubitemid 38101603)
17. Sossalla S, Wagner S, Rasenack EC, et al. Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts-role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol. 2008; 45: 32-43.
18. Sossalla S, Mazur M, Kallmeyer B, et al. Anti-arrhythmic properties of ranolazine and improved diastolic function in isolated human atrial myocardium. J Am Coll Cardiol. 2010; 55: 2330-2342.
19. Hasenfuss G, Maier LS., Mechanism of action of the new anti-ischemia drug ranolazine. Clin Res Cardiol 2008; 97: 222-226. (Pubitemid 351467616)
20. Burashnikov A, Di Diego JM, Zygmunt AC, et al. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation. 2007; 116: 1449-1457. (Pubitemid 47480635)
21. Valdivia CR, Chu WW, Pu J, et al. Increased late sodium current in myocytes from a canine heart failure model and from failing human heart. J Mol Cell Cardiol. 2005; 38: 475-483. (Pubitemid 40331938)
22. Rastogi S, Sharov VG, Mishra S, et al. Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. Am J Physiol Heart Circ Physiol. 2008; 295: H2149-H2155.
23. Hayashida W, van Eyll C, Rousseau MF, et al. Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease. Cardiovasc Drugs Ther 1994; 8: 741-747. (Pubitemid 24376754)
24. Figueredo VM, Pressman GS, Romero-Corral A, et al. Improvement in left ventricular systolic and diastolic performance during ranolazine treatment in patients with stable angina. J Cardiovasc Pharmacol Ther 2010;doi:10.1177/ 1074248410382105.
25. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003; 362: 777-781. (Pubitemid 37093918)
26. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005; 26: 215-225. (Pubitemid 40222359)
27. Burlew BS, Weber KT., Cardiac fibrosis as a cause of diastolic dysfunction. Herz. 2002; 27: 92-98. (Pubitemid 34309394)
28. Schellings MW, Pinto YM, Heymans S., Matricellular proteins in the heart: possible role during stress and remodeling. Cardiovasc Res. 2004; 64: 24-31. (Pubitemid 39208920)